Stoke Therapeutics, Inc.
STOK
Rank in Stocks
#6308
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to... Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
Share Price
$27.71
Last synced: 2026-11-09
Market Cap
$1.80B
Change (1 day)
4.41%
Change (1 year)
10.35%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Stoke Therapeutics, Inc. (STOK)
Category
Healthcare
Operating Margin for Stoke Therapeutics, Inc. (STOK)
Operating Margin as of November 2026 TTM: -913.12%
According to Stoke Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is -913.12%. At the end of 2025 the company had an operating margin of -11.16%.
Operating Margin history for Stoke Therapeutics, Inc. from 2017 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -913.12% | 8,082.08% |
| 2025 | -11.16% | -95.98% |
| 2024 | -277.31% | -78.79% |
| 2023 | -1,307.21% | 55.39% |
| 2022 | -841.24% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.04% |
US
|
|
| -149.01% | -99.84% |
US
|
|
| 25.57% | -100.03% |
AU
|
|
| 31.23% | -100.03% |
BE
|
|
| 29.35% | -100.03% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Stoke Therapeutics, Inc.'s operating margin
What is Stoke Therapeutics, Inc.'s operating margin?
Stoke Therapeutics, Inc.'s operating margin is -913.12%, as of Nov 2026.
What was Stoke Therapeutics, Inc.'s operating margin in 2025?
In 2025, Stoke Therapeutics, Inc.'s operating margin was -11.16%, compared with -277.31% in 2024.
How has Stoke Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Stoke Therapeutics, Inc.'s operating margin was highest in 2021 (0.00%) and lowest in 2023 (-1,307.21%).
How does Stoke Therapeutics, Inc.'s operating margin compare with similar companies?
Stoke Therapeutics, Inc.'s operating margin (-913.12%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.